News

FUJIFILM Diosynth Biotechnologies and Regeneron Sign a 10-year U.S. Manufacturing Agreement Valued at Over $3 Billion
Agreement secures additional U.S. manufacturing capacity to help ensure patient access to medicineHOLLY SPRINGS, N.C., April 23, 2025 -- ...
Regeneron Expands US Manufacturing With $3 Billion Fujifilm Deal
Regeneron signs $3 billion deal with FUJIFILM to expand biologics manufacturing in North Carolina, boosting U.S. capacity and ...
Westfair Communications17h
FujiFilm Diosynth Biotechnologies signs $3B agreement with Regeneron
Regeneron employee works on a pharmaceutical drug. Photo courtesy of Regeneron Pharmaceuticals HOLLY SPRINGS, N.C. – FujiFilm Diosynth Biotechnologies today announced ...
Regeneron to invest over $3 billion to boost US manufacturing
Regeneron Pharmaceuticals said on Tuesday it had entered into a deal valued at more than $3 billion with contract drug ...
Contract Pharma18h
Fujifilm Diosynth Biotechnologies & Regeneron Sign 10-Year U.S. Manufacturing Agreement
The agreement is valued at over $3 billion and increases U.S. manufacturing capacity to help ensure patient access to ...
Regeneron Inks $3 Billion Fujifilm Deal to Bolster US Drugmaking
Regeneron Pharmaceuticals Inc. agreed to pay Fujifilm Diosynth Biotechnologies more than $3 billion over the next decade to ...
Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...